The tablet formulation of zanubrutinib (Brukinsa; BeOne) is now permitted for all five indications across numerous hematological cancers.Nala's MLD was recognized also late for her to generally be treated. She's now struggling to wander or converse, and needs to be tube-fed.End result of early juvenile onset MLD right after unrelated twine blood tr